Public signal · 1-minute delayed

Signal brief

Source-backed market context you can read and share without an account.

CHRNBullishCorporate Developmentsnews

High materiality9/10

ChronoScale Targets $1B AI Revenue Run-Rate by 2027; Ekso Bionics Sale Completed

Oct 1, 2026, 5:49 PM EDT1 sourcesAI-analyzed

Why it may matterVerify against the original reporting

Two major contract wins expand revenue visibility and push the 2027 run-rate target higher, while the Ekso Bionics sale reduces distraction and reallocates capital to core AI infra. Yet, execution and capital-raising risks could temper near-term upside; nonetheless, the combination strengthens CHRN's long-run growth narrative.

AI summary

What happened, with direct paths to the underlying reporting

ChronoScale announced expansion of an existing AI infrastructure contract and a new customer, expanding its deployment pipeline and targeting a $1 billion annualized revenue run-rate by Q3 2027. The company also completed the sale of the Ekso Bionics unit to sharpen focus on its AI infrastructure business.

Expands existing AI infrastructure contract and signs a new customer.
Annualized revenue run-rate targeted at $1B by calendar Q3 2027.
ChronoScale completes Ekso Bionics business unit sale to focus on core AI infra.
Management emphasizes disciplined execution and capacity scaling.

How to read this signal

Transparent limits for an AI-generated research aid

StockNews.AI groups source reporting, classifies the event, and measures subsequent price movement. This is informational research, not investment advice. Prices may be delayed or unavailable.